Inhalation Anesthesia Global Market Report 2026

Inhalation anesthesia refers to medications administered in operating rooms to induce and maintain general anesthesia. Along with other therapeutic effects, these agents cause varying levels of sedation, ranging from mild drowsiness to deep unconsciousness, including full general anesthesia. Inhalation anesthesia is commonly used for both the induction and maintenance of general anesthesia during surgical procedures.

The main products in the inhalation anesthesia market include sevoflurane, desflurane, isoflurane, and nitrous oxide. Isoflurane is an inhaled general anesthetic used to initiate and sustain general anesthesia. It works by relaxing muscles and decreasing pain sensitivity through alterations in tissue excitability. The applications of inhalation anesthesia include induction and maintenance of anesthesia, and the primary end users are hospitals and ambulatory surgical centers.

Tariffs have impacted the inhalation anesthesia market by increasing the cost of importing anesthetic gases, precision delivery equipment, and monitoring devices. Hospitals and ambulatory surgical centers in regions such as Asia-Pacific and Europe face higher procurement costs, particularly for imported Sevoflurane and Desflurane. While some domestic manufacturers benefit from reduced foreign competition, overall supply chain delays have led to cost optimization strategies and increased investment in local production and innovation of efficient anesthesia solutions.

The inhalation anesthesia market research report is one of a series of new reports from The Business Research Company that provides inhalation anesthesia market statistics, including inhalation anesthesia industry global market size, regional shares, competitors with a inhalation anesthesia market share, detailed inhalation anesthesia market segments, market trends and opportunities, and any further data you may need to thrive in the inhalation anesthesia industry. This inhalation anesthesia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhalation anesthesia market size has grown strongly in recent years. It will grow from $1.64 billion in 2025 to $1.78 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising surgical procedures, increasing hospital investments, technological advancements in anesthesia equipment, growing awareness of patient safety, expanding healthcare infrastructure.

The inhalation anesthesia market size is expected to see strong growth in the next few years. It will grow to $2.51 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to adoption of AI-assisted anesthesia, demand for sustainable anesthetic agents, integration of IoT in operating rooms, growth in outpatient surgeries, development of smart anesthesia delivery systems. Major trends in the forecast period include enhanced patient safety protocols, advanced anesthesia delivery systems, minimally invasive surgery support, real-time anesthesia monitoring, environmentally friendly anesthetic agents.

The growing geriatric population is expected to drive the expansion of the inhalation anesthesia market during the forecast period. An increasing number of older adults is contributing to higher demand for inhalation anesthesia, as this population is more susceptible to degenerative diseases and chronic conditions, which in turn leads to a greater number of surgical procedures and therapeutic interventions. Additionally, the rising elderly population, which is more prone to conditions such as cardiovascular, neurological, respiratory, and degenerative disorders, is further supporting market growth. Administering anesthesia through the intravenous route is often challenging in geriatric patients due to fragile or damaged blood vessels and issues related to patient compliance. For example, in July 2024, the UK Parliament's House of Commons Library, a UK-based government body, reported that in 2022 there were 12.7 million people aged 65 years or older in the UK. This figure is projected to increase to 22.1 million by 2072, representing 27% of the total population. Consequently, the expanding geriatric population is anticipated to increase demand for inhalation anesthesia over the forecast period.

The increasing prevalence of chronic diseases is expected to drive the growth of the inhalation anesthesia market in the coming years. Chronic diseases are long-term health conditions that persist for extended periods, typically lasting three months or longer. Inhalation anesthesia plays a vital role in healthcare, as it is essential for maintaining patient comfort and safety during surgical procedures that are often required for the diagnosis, treatment, or management of many chronic conditions. For example, in September 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that approximately 41 million deaths worldwide-representing 74% of all global deaths-are attributed annually to non-communicable or chronic diseases. These included 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. As a result, the growing burden of chronic diseases is expected to fuel the expansion of the inhalation anesthesia market.

In November 2024, Sedana Medical AB, a Sweden-based supplier of inhaled sedation and inhalation anesthesia products, acquired Innovatif Cekal Sdn Bhd for USD 3.6 million (34 million SEK). Through this acquisition, Sedana Medical seeks to strengthen its supply chain control, reduce manufacturing costs, and secure long-term production capacity for its inhalation anesthesia devices by internalizing the manufacturing of the Sedaconda ACD and its associated accessories. Innovatif Cekal Sdn Bhd is a Malaysia-based company that provides device components and contract manufacturing services for the Sedaconda ACD, a critical device used to deliver volatile inhalation anesthetics to mechanically ventilated patients.

Major companies operating in the inhalation anesthesia market are AbbVie Inc., Baxter International Inc., Sandoz AG, Piramal Enterprises Limited, Fresenius SE & Co KGaA, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co Ltd, Lunan Pharmaceutical Group Co Ltd, Troikaa Pharmaceuticals Ltd, Dechra Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Maruishi Pharmaceutical Co Ltd, Nikko Chemicals (Japan), GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Halocarbon Products Corporation, Abbott Laboratories, Baxter Healthcare (distinct manufacturing division) , Fresenius Kabi AG, Sedana Medical AB

North America was the largest region in the inhalation anesthesia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalation anesthesia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the inhalation anesthesia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inhalation anesthesia market consists of sales of nitrous oxide, halothane, isoflurane, desflurane, and sevoflurane. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inhalation Anesthesia Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses inhalation anesthesia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhalation anesthesia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The inhalation anesthesia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Sevoflurane; Desflurane; Isoflurane; Nitrous Oxide
• 2) By Application: Induction; Maintenance
• 3) By End User: Hospitals; Ambulatory Surgical Centers
• Companies Mentioned: AbbVie Inc.; Baxter International Inc.; Sandoz AG; Piramal Enterprises Limited; Fresenius SE & Co KGaA; Hikma Pharmaceuticals PLC; Jiangsu Hengrui Medicine Co Ltd; Lunan Pharmaceutical Group Co Ltd; Troikaa Pharmaceuticals Ltd; Dechra Pharmaceuticals PLC; Aspen Pharmacare Holdings Limited; Maruishi Pharmaceutical Co Ltd; Nikko Chemicals (Japan); GlaxoSmithKline PLC; Boehringer Ingelheim International GmbH; Halocarbon Products Corporation; Abbott Laboratories; Baxter Healthcare (distinct manufacturing division) ; Fresenius Kabi AG; Sedana Medical AB
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.